BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novartis AG (NVS) Drug Works to Treat Rare Cushing's Disease


11/5/2012 8:18:13 AM

Novartis AG (NOVN)’s treatment for Cushing’s disease works, potentially providing a second marketed therapy for the rare condition, U.S. regulators said. The drug known as pasireotide decreases levels of the hormone cortisol, which in excess cause Cushing’s, Food and Drug Administration staff said today in a report. The disease leads to obesity, skin that bruises easily, excess hair growth in women and decreased sexual desire in men, according to the National Institutes of Health. The drug, which Basel, Switzerland-based Novartis proposes calling Signifor and is approved in Europe, would be an alternative to surgery to remove tumors that are the cause of the excess hormone. The FDA approved in February the first treatment for Cushing’s, which is a once-daily pill from Corcept Therapeutics Inc. (CORT) called Korlym. An FDA advisory committee is scheduled on Nov. 7 to review the therapy.

Read at Bloomberg

Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES